(Total Views: 599)
Posted On: 03/08/2021 11:17:38 PM
Post# of 148903
The last few days I have been ripped on this board for putting out what normal companies do in a situation like this. I stated the board of directors needs to look closely at reviewing the COVID program and, if they feel it is in any way potentially negatively impacting focus on HIV and Cancer, or is jeopardizing the company”s financial situation , to pull out of Covid and call it a day. Realistically , if we stay in covid, id dump any cd12 related additional studies and just do long haulers , even though it’s in an earlier stage because it has a lasting impact on people long after this pandemic goes away, while the need for Leronlimab for critical is going to diminish as the pandemic fades and other drugs such as Merck may continue to shrink our opportunity.
The second part of that is Dr Kelly, as chairman along with the board needs to evaluate if the current CEO to see if a change is needed to get a much needed drug into the market for HIV and cancer ..HIV is the disease most likely to get approval within the next year. Sugar coating the BLA failure last summer costing us a year and now 2 CD trial failures is enough to seriously look at making the management change, especially when he is pounding his chest continuing to talk about triple digit stock prices. Right now we would be happy with low double digits at this point. NP did a great job in having the foresight to buy Leronlimab for a very cheap price but his inexperience , pride, and ego, are getting in the way of this drug getting to market as a Cytodyn owned product. The next 30-60 days are incredibly critical to the company and there is time to right the ship to focus on HIV and get it over the finish line or, if the board concludes the only option to get leronlimab to the market is to sell the company, then they need to do so.. It is apparent to me that although the Covid route seemed Promising , it was a critical mistake made by NP to spend the last 10 months focused on this disease. People can complain about Bp, the FdA , etc but this is the landscape of this playing field, like it or not. You have to play with those cards you have . You can’t complain about them after you lose hand after hand.
The second part of that is Dr Kelly, as chairman along with the board needs to evaluate if the current CEO to see if a change is needed to get a much needed drug into the market for HIV and cancer ..HIV is the disease most likely to get approval within the next year. Sugar coating the BLA failure last summer costing us a year and now 2 CD trial failures is enough to seriously look at making the management change, especially when he is pounding his chest continuing to talk about triple digit stock prices. Right now we would be happy with low double digits at this point. NP did a great job in having the foresight to buy Leronlimab for a very cheap price but his inexperience , pride, and ego, are getting in the way of this drug getting to market as a Cytodyn owned product. The next 30-60 days are incredibly critical to the company and there is time to right the ship to focus on HIV and get it over the finish line or, if the board concludes the only option to get leronlimab to the market is to sell the company, then they need to do so.. It is apparent to me that although the Covid route seemed Promising , it was a critical mistake made by NP to spend the last 10 months focused on this disease. People can complain about Bp, the FdA , etc but this is the landscape of this playing field, like it or not. You have to play with those cards you have . You can’t complain about them after you lose hand after hand.
(4)
(1)Scroll down for more posts ▼
